Adam Rosenberg

[Ambagon Therapeutics @ambagontx]

Our platform consists of three fundamental elements: our drug discovery toolbox, 14-3-3 encyclopedia and diverse compound library. Each helps us expand the druggable proteome. To find additional details about our platform, visit our site at https://t.co/3QKC1SygxX

[Adam Rosenberg @aj_rosenberg]

@LifeSciVC Then you really had no excuse passing on our zebrafish company

[Adam Rosenberg @aj_rosenberg]

The father of a Harry Potter fan tries to shed some light on the role of EIRs and venture partners @ biotech vcs https://t.co/k8jXkpOQDm

[Marian T. Nakada @MNakada]

Want to make a difference for our troops? Please check out #SneakersForSoldiers and my testimonial on ABC World News Tonight #AmericaStrong

https://t.co/xoRLPPmjr1

[Julian Edelman @Edelman11]

RIP Flossie Wong-Staal, an American hero AND daughter of China. 1st to clone HIV, leading to treatments saving lives. Proof the world can work together.❤️

[Adam Rosenberg @aj_rosenberg]

Definitely better than a zoom graduation https://t.co/cRdO7msCGv

[Adam Rosenberg @aj_rosenberg]

@LifeSciVC @alexharding @endpts @atlasventure Congrats @alexharding - a rockstar in the board room and the emergency room (and allegedly the rugby pitch as well)

[Adam Rosenberg @aj_rosenberg]

More evidence for SV2A PET as a marker of synaptic density https://t.co/uyNBhsGr6x

[Jeb Keiper @JebKeiper]

Anyone investing or operating early stage drug discovery ought to give a read for the lessons learned here, and read through the end to get to the "why" - moving lessons about patients we all know, and why we do what we do.

[Bruce Booth @LifeSciVC]

Thinking Boldly: Alkermes Acquires Rodin Therapeutics. https://t.co/3WpvXFyAWg $ALKS

[Adam Rosenberg @aj_rosenberg]

Very proud of what our team ⁦@Rodintx⁩ has accomplished over 4+ years of cutting-edge research in challenging neurological areas with massive unmet need - look forward to continued progress ⁦@Alkermes⁩ https://t.co/Y2wte9b1W3

[Adam Rosenberg @aj_rosenberg]

@LifeSciVC @Bobmorevc That’s a very average response. But at least it wasn’t a mean response.

[Adam Rosenberg @aj_rosenberg]

@LifeSciVC Wait, I thought it was our audit committee call you were on at the time that made your commute less painful?

[Adam Rosenberg @aj_rosenberg]

Excellent thread on capital efficiency by @epaley; relevant to tech and biotech

[Eric Paley @epaley]

Imagine your startup had a billion dollars in the bank today. How fast would you spend it?

Default is time-based. Founders hire, commission projects, and spend on acquisition channels with the goal of surpassing the previous round’s valuation in 18-24 months.

1/11

[Adam Rosenberg @aj_rosenberg]

Great piece by Halley Gilbert of @allergyamulet, @ironwoodpharma and @biodirector1 on overseas family travel with #foodallergies (and yes, I am the unnamed food suitcase advisor...)

[Amulet @amulet_tech]

Top tips for staying safe while traveling abroad with #foodallergies on today’s blog!

https://t.co/7UiXYWHcwh

[Adam Rosenberg @aj_rosenberg]

Excited for Ajim to join the team!

[Rodin Therapeutics @Rodintx]

Today we announced the appointment of Ajim Tamboli as chief financial officer. Ajim joins Rodin with more than 20 years of experience as a healthcare investor and advisor. Read more: https://t.co/mGdocXjnlm

[Adam Rosenberg @aj_rosenberg]

Great piece re: the power of #zebrafish for in vivo drug screening; faster, cheaper and least in some cases, preferable to rodents

[sharon begley @sxbegle]

The fish that saved a dying boy. No, not Flipper: WES, recombinant DNA, #zebrafish, #precisionmed. https://t.co/TvxntooSQo

[Bluefield Project @BluefieldProj]

Thanks @jonrohrer and @FTDtalk for a terrific #GENFI Therapeutics Meeting about clinical, cognitive, imaging and fluid biomarker outcome measures in genetic #FTD. And congratulations on reaching 1000 GENFI participants!

[Adam Rosenberg @aj_rosenberg]

Great job by entire @Rodintx team to achieve this important milestone on the way towards making a difference for patients with neurologic disease; while this may get a bit lost in today’s other news, designing a novel molecule and reaching clinical safety data is no small feat!

[Rodin Therapeutics @Rodintx]

Today we announced positive Phase 1 results supporting continued clinical development of RDN-929, a potent and selective HDAC-CoREST inhibitor, for the treatment of #synaptopathies. Learn more here: https://t.co/0FgObEfDPs

[Steven Sweeney @nutoxman]

An Ironman’s Fight against Parkinson’s https://t.co/YgSDOoDxa4